The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Moving towards personalized therapy in CLL & sequencing BTK inhibitors
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, talks on personalizing therapy for patients with chronic lymphocytic leukemia (CLL), commenting on the optimal strategy to sequence BTK inhibitors. According to Dr Woyach, it is best to start with a covalent BTK inhibitor and then continue with a non-covalent BTK inhibitor. Additionally, Dr Woyach highlights the advent of non-covalent BTK inhibitors, which hold great promise both alone or in combination with other agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm Therapeutics: Research Funding; Schrodinger: Research Funding; Newave: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; ArQule: Consultancy; MorphoSys: Consultancy, Research Funding; Loxo@Lilly: Research Funding; AbbVie: Consultancy, Research Funding; Janssen: Consultancy; BeiGene: Consultancy; AstraZeneca: Consultancy.
